Introduction {#s1}
============

The main clinical symptoms of spasticity, hyperreflexia and spasms, develop after spinal cord injury (SCI) due in part to the hyperexcitability of motoneurons ([@bib35]; [@bib28]; [@bib57]; [@bib23]; [@bib70]). Understanding the cellular pathophysiological processes underlying this hyperexcitability might offer new therapeutic perspectives for spasticity.

SCI enhances the intrinsic excitability of motoneurons by upregulating their persistent sodium (*I*~NaP~) and calcium (*I*~CaP~) currents, leading to muscle spasms and hyperreflexia in both humans and adult rats ([@bib48]; [@bib46]; [@bib31]; [@bib33]; [@bib32]; [@bib26]; [@bib69]; [@bib15]). In addition, a concomitant synaptic disinhibition of motoneurons due to a decrease of the main chloride extruder KCC2 also takes place after SCI in both humans and adult rodents ([@bib11]; [@bib54]; [@bib44]). In vitro experiments from neonatal rats show that this form of disinhibition stems primarily from an impaired Cl^−^ extrusion, typically identified by a depolarizing shift of the reversal potential of inhibitory postsynaptic potentials (*E*~IPSP~) ([@bib11]), which may facilitate the recruitment of persistent inward currents after SCI ([@bib74]). Thus, up-regulation of persistent inward currents concomitant with down-regulation of KCC2 may have a synergistic effect causing spasticity.

Remarkable advances have been made in the molecular mechanisms involved in alterations of persistent inward currents after SCI. SCI-induced constitutive 5-HT~2B/C~ receptor activity leads to an increase in *I*~CaP~ ([@bib55]), while calpain-mediated proteolysis of Nav1.6 channels up-regulates *I*~NaP~ ([@bib15]). Although the *mechanisms* involved in alterations of KCC2 after SCI remain elusive, it is worth mentioning that calpain-mediated cleavage of KCC2 depolarizes the *E*~IPSP~ in some pathophysiological conditions ([@bib59]; [@bib82]; [@bib77]). Our study investigates whether SCI-induced activation of calpains is upstream of the *up- and down-regulation of I~NaP~* and KCC2 in motoneurons after SCI. If so, we aim at demonstrating whether a cooperation between calpain-mediated alterations of *I*~NaP~ and *E*~IPSP~ is a necessary element driving spasticity. For this purpose, we characterized signs of spasticity from the neonatal rat SCI model to obtain easier in vitro correlates of the hyperexcitability of lumbar motoneurons controlling hindlimb muscles.

Results {#s2}
=======

Symptoms of spasticity in neonatal rats develop few days after SCI {#s2-1}
------------------------------------------------------------------

Signs of spasticity (spontaneous muscle spasms, hyperreflexia) have been reported to emerge in adult rats weeks after a thoracic spinal transection ([@bib21]). Here, we identified signs of spasticity 4**--**5 days (d) after a thoracic transection performed within the first 12 hr (hrs) after birth in neonatal rats. Instead of a brief kicking of hindlimbs in response to the tail-pinch test ([Figure 1A](#fig1){ref-type="fig"} and [Figure 1---video 1](#fig1video1){ref-type="video"}), rats with SCI displayed hindlimb hyperextension characterized by long-lasting EMG activity recorded from triceps surae extensor muscles (p\<0.001; [Figure 1A--C](#fig1){ref-type="fig"} and [Figure 1---video 2](#fig1video2){ref-type="video"}). In addition, the *threshold for response* to mechanical stimuli was significantly reduced (p\<0.05; [Figure 1D](#fig1){ref-type="fig"}). Rats with SCI resting on a heated plate at 34°C ([Figure 1E](#fig1){ref-type="fig"}) showed a higher number of spontaneous muscle twitches from the tail and hindlimbs compared to sham-operated rats (p\<0.001; [Figure 1F](#fig1){ref-type="fig"} and [Figure 1---videos 3](#fig1video3){ref-type="video"}--[4](#fig1video4){ref-type="video"}). In sum, behavioral indicators of spasticity emerge a few days after SCI in neonatal rats.

![Calpain inhibition alleviates early behavioral signs of spasticity in neonatal rats with SCI.\
(**A,B**) Pictures of typical hindlimb motor response to tail pinching in sham-operated (**A**), *n* = 6 rats) and SCI rats (**B**), 5 d post-SCI, *n* = 8 rats). Lower and upper traces represent the pinch force and the evoked electromyographic (EMG) response of the triceps surae muscle, respectively. (**C,D**) Group means quantification of EMG responses. \*p\<0.05, \*\*\*p\<0.001 comparing sham versus SCI groups; Mann-Whitney test. (**E**) Groups means quantification of twitches over a time period of 10 min obtained from sham-operated and SCI rats (5 d post-SCI) at rest on heating pad (\~34.5°C). \*\*\*p\<0.001 comparing sham versus SCI groups (*n* = 22 rats in both groups); Mann-Whitney test. (**F**) Time-course changes of twitches after acute i.p. administration (t = 0) of vehicle (black, *n* = 5 rats) or MDL28170 at 60 mg/kg (red, *n* = 5 rats) or MDL28170 at 120 mg/kg (green, *n* = 5 rats) in SCI neonatal rats (5 d post-SCI). \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, repeated measures one-way ANOVA, Dunnett's post-test. (**G**) Representative EMG responses of the triceps surae muscle to tail pinching in SCI neonatal rats (5 d post-SCI) 60 min after an acute i.p. administration of vehicle (black, *n =* 9 rats) or MDL28170 (red, 120 mg/kg, *n =* 6 rats). Lower traces represent the pinch force. Group means quantification of EMG responses on the right-hand side. \*p\<0.05; comparing vehicle-treated versus MDL28170-treated rats; Mann-Whitney test. Underlying numerical values can be found in the [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}.\
Figure 1---source data 1.Values displayed in bar plots in [Figure 1C-G](#fig1){ref-type="fig"}.](elife-51404-fig1){#fig1}

Acute inhibition of calpain reduces spasticity symptoms in neonatal SCI rats {#s2-2}
----------------------------------------------------------------------------

The activation of calpain contributes to spasticity in adult rats with chronic SCI ([@bib15]). We assessed whether a similar molecular mechanism exists in SCI neonatal rats. The acute intraperitoneal injection (i.p.) of MDL28170 at minimal or maximal effective doses for the reduction of calpain activity in the CNS ([@bib42]; [@bib71]), dose-dependently reduced the number of spontaneous muscle twitches (p\<0.001; [Figure 1G](#fig1){ref-type="fig"}). At the highest dose (120 mg/kg), twitches were less frequent up to 9 hr compared to vehicle-treated animals and temporarily dropped to levels similar to those found in intact animals over a period from 2 to 5 hr post-injection ([Figure 1G](#fig1){ref-type="fig"}, *dashed line*). Note that MDL28170 used at 120 mg/kg did not reduce spontaneous twitches in sham-operated animals suggesting that the effect of the drug was specific to rats with SCI and did not result from lethargy (p\>0.05; [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). In addition to spasms reduction, the acute inhibition of calpains with MDL28170 decreased the duration of EMG responses to tail-pinch in SCI neonatal rats (p\<0.05, [Figure 1H](#fig1){ref-type="fig"}) without affecting the threshold to mechanical stimuli (p\>0.05, [Figure 1H](#fig1){ref-type="fig"}). In sum, data revealed a causal relationship between the activation of calpain and the development of spasticity in the neonatal SCI model.

The expression of Calpain-I increased after SCI {#s2-3}
-----------------------------------------------

In the CNS, calpains exist in two major isoforms: µ-calpain (or calpain-I) and m-calpain (or calpain-II). To determine whether these calpains showed changes in their expression after SCI, we performed Western blots on lumbar spinal cord tissue isolated from 5-d old rats. Immunoblots revealed a SCI-induced increase in expression of calpain-I in both its forms (the 110 kDa inactive proenzyme and the 80 kDa active catalytic subunit; p\<0.05; [Figure 2](#fig2){ref-type="fig"}). Expression of calpain-II did not change after SCI (p\>0.05; [Figure 2](#fig2){ref-type="fig"}).

![The expression of Calpain-I increased after SCI.\
*On the left*, calpain-I and calpain-II immunoblots of lumbar segments in sham-operated (*n* = 4 rats) and SCI neonatal rats (5 d post-SCI, *n* = 4 rats). One rat per lane. *On the right*, group means quantification of bands of both calpain-I and calpain-II in SCI rats normalized to sham-operated controls. \*p\<0.05 comparing sham versus SCI groups; Mann-Whitney test. Data are means ± SD. Underlying numerical values can be found in the [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}.\
Figure 2---source data 1.Values displayed in bar plots in [Figure 2](#fig2){ref-type="fig"}.](elife-51404-fig2){#fig2}

Early appearance of hyperexcitability to caudal spinal cord after SCI {#s2-4}
---------------------------------------------------------------------

We investigated whether the in vivo emergence of spasticity correlated with an early appearance of hyperexcitability within the sublesional spinal cord. In isolated spinal cords from sham-operated rats, a supramaximal stimulation of the 5^th^ lumbar (L5) dorsal root elicited a typical short-lasting response in the homologous ventral root (SLR, black traces; [Figure 3A--C](#fig3){ref-type="fig"}) with the presence of the monosynaptic reflex (arrows in insets; [Figure 3A--C](#fig3){ref-type="fig"}). The SLR (the early transient 40 ms response) did not change regardless of age (p\>0.05, in black, [Figure 3D--G](#fig3){ref-type="fig"}). By contrast, the SLR gradually increased after SCI (p\<0.001, in red, [Figure 3D--G](#fig3){ref-type="fig"}) and a long-lasting reflex (LLR, red traces; [Figure 3A--C](#fig3){ref-type="fig"}), almost absent in sham-operated rats, was noticeable 24 hr post-surgery. Note that an interpulse interval of at least 4 min was required to avoid a use-dependent decline of the LLR ([Figure 3---figure supplement 1A--D](#fig3s1){ref-type="fig"}). The LLR gradually increased after SCI and differed significantly from sham-operated rats as early as 2--3 d post-SCI (p\<0.001, [Figure 3H](#fig3){ref-type="fig"}), transforming the unimodal peristimulus time histograms (PSTHs) into a bimodal distribution ([Figure 3D--F](#fig3){ref-type="fig"}). One week after SCI, the LLR lasted 9.0 ± 0.6 s (*n* = 52 spinal cords, [Figure 3C](#fig3){ref-type="fig"}) and the stimulus threshold was markedly decreased (p\<0.001, [Figure 3I](#fig3){ref-type="fig"}). At this age, in 16/52 (\~31%) of our preparations, the LLR appeared as a fictive locomotor episode characterized by a rhythmic alternation and a negative cross-correlation between opposite ventral root activities ([Figure 3C](#fig3){ref-type="fig"}; *bottom traces*). This locomotor-like activity could not be evoked in sham-operated rats by a single pulse stimulation.

![Early development of hyperexcitability on caudal spinal cord after SCI.\
(**A--C, J--L**) Representative L5 ventral root activities (VR L5) evoked by a supramaximal stimulation (St.) of the ipsilateral dorsal root (**A--C**) or occurring spontaneously (**J--L**) in spinal cords isolated 1 d (**A, J**), 2--3 d (**B,K**) or 4--5 d (**C,L**) after sham surgery (black) or SCI (red) \[for **A--C**: 1 d, *n* = 24 sham and *n* = 6 SCI; 2--3 d, *n* = 29 sham and *n* = 10 SCI; 4--5 d, *n* = 52 in both groups; for **J--L**: 1 d, *n* = 12 sham and *n* = 7 SCI; 2--3 d, *n* = 11 sham and *n* = 12 SCI; 4--5 d, *n* = 10 sham and *n* = 17 SCI\]. Insets in (**A--C**) are enlargements of the monosynaptic reflex while single arrows indicate the monosynaptic reflex and the stimulus artifact (St.). Bottom traces in (**C**) illustrate a dorsal root-evoked alternating locomotor-like activity recorded from opposite L5 ventral roots, with the corresponding cross-correlation histograms for left/right relationship. Parts of the recordings in J--L indicated by shaded areas are shown at a faster time scale on the right-hand side. (**D--F**) Average peristimulus time histogram (PSTH, bin width: 20 ms) of dorsal root evoked L5 ventral root responses collected from sham-operated (black) or SCI rats (red) 1 d (**D**), 2--3 d (**E**) or 4--5 d (**F**) post-SCI. (**G--I,M--O**) Group means quantification of: events per rat detected over time windows of 10--40 ms and 500--15,000 ms post-stimulus for SLR and LLR, respectively (**G,H**), threshold for evoking ventral root responses (**i**) and of spontaneous activites (**M--O**) at different time points post-SCI. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 comparing sham versus SCI groups; two-way ANOVA, Bonferroni's post-test. Data are means ± SD. Underlying numerical values can be found in the [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}.\
Figure 3---source data 1.Values displayed in bar plots shown in [Figure 3G-I, M-O](#fig3){ref-type="fig"}.](elife-51404-fig3){#fig3}

Stable spontaneous non-evoked motor bursts were also recorded from L5 ventral roots within the first hr after the spinal cord was placed in the recording chamber ([Figure 3J--L](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1E--F](#fig3s1){ref-type="fig"}). The spontaneous motor bursts decreased in frequency during the first postnatal week in both SCI and sham-operated animals (black traces; [Figure 3J--M](#fig3){ref-type="fig"}), but were more frequent at all ages after SCI (red traces, p\<0.001; [Figure 3J-M](#fig3){ref-type="fig"}). Spontaneous bursts also increased in both amplitude and duration with age after SCI, and were much more pronounced 4--5 d after SCI compared to sham-operated controls (p\<0.001; [Figure 3N--O](#fig3){ref-type="fig"}). Sometimes spontaneous activities appeared as oscillatory bursts resembling locomotor-like episodes exclusively observed in SCI animals. Thus, an early increase of spinal hyperexcitability occurred after SCI and led to excessive spontaneous and sensory-evoked motor outputs consistent with behavioral signs of spasticity observed from SCI neonatal rats.

Calpain is upstream of the hyperexcitability of SCI motoneurons {#s2-5}
---------------------------------------------------------------

To further study the role of calpain activity in spasticity, we examined the acute effects of MDL28170 on the spinal cord hyperexcitability in vitro (from 4 to 5 d post-SCI). Bath-applied MDL28170 (30 µM, 60 min) reduced dorsal root-evoked ventral root responses ([Figure 4A](#fig4){ref-type="fig"}) to the point that the PSTH approximated a unimodal distribution ([Figure 4B](#fig4){ref-type="fig"}). Both SLR and LLR decreased (p\<0.05; [Figure 4C](#fig4){ref-type="fig"}) without affecting the monosynaptic reflex (p\>0.05; insets in [Figure 4A](#fig4){ref-type="fig"} and histograms in [Figure 4C](#fig4){ref-type="fig"}). However, LLR remained higher compared to responses recorded in spinal cords from sham-operated rats (p\<0.01). Likewise, spontaneous bursting activity became scarce, shorter and smaller in the presence of MDL28170 (p\<0.05; [Figure 4D--E](#fig4){ref-type="fig"}) and did not differ from that recorded in sham animals (p\>0.05). In adult rats, we previously demonstrated a causal relationship between calpain-mediated cleavage of Nav1.6 channels, up-regulation of *I*~NaP~, and spasticity ([@bib15]). Consistent with these results, SCI in neonates enhanced a calpain-mediated cleavage of Nav channels, as pointed out by the increased density of a \~ 120 kDa band on membrane fraction of Western blots probed by a pan-Nav antibody ([Figure 4F](#fig4){ref-type="fig"}, *left lane*). This band was almost absent in intact animals (see Figure 4A in [@bib15]). Interestingly, the acute bath application of MDL28170 reduced the \~120 kDa fragment (p\<0.05; [Figure 4F](#fig4){ref-type="fig"}, *right lane*) without affecting the prominent \~250 kDa representing the full-length form of Nav channels (p\>0.05; [Figure 4F](#fig4){ref-type="fig"}). Consistent with, the MDL28170-induced decrease of the \~120 kDa fragment observed on membrane fraction was associated with a decrease in the density of immunostaining for Nav1.6, the main α-subunits expressed at the axon initial segment of lumbar motoneurons (p\<0.001; [Figure 4G](#fig4){ref-type="fig"}). We performed voltage-clamp recordings in spinal cord slices to examine the functional impact of MDL28170 on biophysical properties of *I*~NaP~ in lumbar SCI motoneurons. MDL28170 reduced by 16% the amplitude of *I*~NaP~ (p*\<*0.05; [Figure 4H](#fig4){ref-type="fig"}) without affecting its voltage activation threshold (p*\>*0.05; [Figure 4H](#fig4){ref-type="fig"}). In contrast, MDL28170 did not change *I*~NaP~ recorded from motoneurons in sham-operated controls (p\<0.05; [Figure 4---figure supplement 1A--B](#fig4s1){ref-type="fig"}).

![Inhibition of calpain restores the excitatory/inhibitory equilibrium of motoneurons.\
(**A,D**) Representative L5 ventral root activities (VR L5) evoked by a supramaximal stimulation (St.) of the ipsilateral dorsal root (**A**) or occurring spontaneously (**D**) in spinal cords isolated from SCI rats (4--5 d post-SCI; *n* = 6 rats) before (black) and after (red) bath-applying MDL28170 (30 µM, 60 min). Insets in (**A**) illustrate enlargements of the monosynaptic response. (**B**) Average peristimulus time histogram (PSTH, bin width: 20 ms) of dorsal root evoked L5 ventral root responses before (black) and after (red) adding MDL28170. (**C,E**) Group means quantification of: the monosynaptic reflex and events per rat detected over time windows of 10--40 ms and 500--15,000 ms post-stimulus for SLR and LLR, respectively (**C**) and of spontaneous activities (**E**). \*p\<0.05, comparing data collected before (black) and after MDL28170 (red); Wilcoxon paired test. (**F,I**) Pan-Nav (**F**) and KCC2 (**I**) immunoblots of lumbar segments from SCI rats (5 d post-SCI) bath-applied with vehicle (left lane) or MDL28170 (30 µM, right lane). On the right-hand side, quantification of immunoblots in MDL28170-treated samples (red, *n =* 12 rats for Pan-Nav, *n* = 8 rats for KCC2) normalized to vehicle-treated samples (black, *n =* 11 rats for Pan-Nav, *n =* 7 rats for KCC2). \*p\<0.05; comparing vehicle- to MDL28170-treated samples; Mann-Whitney test. (**G,J**) Representative single optical sections showing immunostaining in vehicle- (left) and MDL28170-treated (right) lumbar enlargement (**L4--L5**) from SCI rats (5 d post-SCI), against Nav1.6 α-subunit expressed in AISs of motoneurons (**G**) or KCC2 expressed in ventral horns (**J**). Asterisks in (**G**) indicate the motoneuron nucleus position and arrows their AISs. Dotted circles in (**J**) surround the ROI where KCC2 staining was quantified. Scale bars, 20 µm and 40 µm in (**G**) and (**J**), respectively. On the right-hand side, relative immunostaining intensities obtained with Nav 1.6 (**G**) and KCC2 (**J**) antibodies in MDL28170-treated samples (red) normalized to vehicle-treated controls (black). For Nav 1.6: *N* = 71 cells each from three rats per group; For KCC2: *N* = 47 slices each from three rats per group. \*p\<0.05, \*\*\*p\<0.001 comparing vehicle-treated versus MDL28170-treated groups; *t*-test. (**H**) Representative leak-subtracted *I*~NaP~ in a lumbar motoneuron (visualized as the largest cells located in layer IX of slices) from SCI rat (5 d post-SCI) and evoked by a slow (12 mV/s) voltage ramp increase from −70 mV to −10 mV over 5 s before (black) and after (red) bath-applying MDL28170 (30 µM, 30--60 min, *n* = 6 cells). Quantification of *I*~NaP~ on the right-hand side. \*p\<0.05, Wilcoxon paired test. (**K**) IPSPs evoked by stimulation (St.) of the ventral funiculus of the spinal cord at different holding potentials in a lumbar motoneuron (identified by the antidromic response to stimulation of the ventral roots) from SCI rat (5 d post-SCI) before (black) and after (red) bath-applying MDL28170 (30 µM, 30--60 min, *n* = 7 cells). Quantification of E~IPSP~ (left) and driving force (E~IPSP~-V~rest~, right) on the right-hand side. \*p\<0.05; Wilcoxon paired test (*n* = 7 cells). Data are mean ± SD. Underlying numerical values can be found in the [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}.\
Figure 4---source data 1.Values displayed in [Figure 4C, E-K](#fig4){ref-type="fig"}.](elife-51404-fig4){#fig4}

In addition to the up-regulation of *I*~NaP~, down-regulation of KCC2 after SCI disinhibits motoneurons and leads to spasticity as well ([@bib11]). However, a causal relationship between calpain and the down-expression of KCC2 after SCI has never been explored. Bath-applied MDL 28170 increased by 21% the expression of KCC2 in its oligomeric \~240 kDa form (p*\<*0.05; [Figure 4I](#fig4){ref-type="fig"}) without affecting the monomeric \~140 kDa form (p*\>*0.05; [Figure 4I](#fig4){ref-type="fig"}). Furthermore, the addition of calpain-I in spinal cord homogenates from intact neonatal rat, dose-dependently reduced the expression of KCC2 (p\<0.01; [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). By immunohistochemical staining, we analyzed the expression of KCC2 on the pool of lumbar (L4-L5) motoneurons. MDL 28170 increased KCC2 staining in the lateral ventral horn where motoneurons are located (p\<0.05; [Figure 4J](#fig4){ref-type="fig"}). We further studied the functional impact on E~IPSP~ which was previously shown to be depolarized in lumbar motoneurons from neonatal rats with SCI ([@bib11]; [@bib8]). Acute bath application of MDL28170 hyperpolarized motoneuronal E~IPSP~ (p\<0.05, [Figure 4K](#fig4){ref-type="fig"}). Because MDL28170 had no effect on the resting membrane potential (V~rest~), the driving force on chloride (E~IPSP~-V~rest~) was significantly more negative (p\<0.05, [Figure 4K](#fig4){ref-type="fig"}). MDL28170 had no effect on *E*~IPSP~ of motoneurons recorded from sham-operated animals (p\<0.05; [Figure 4---figure supplement 1C--D](#fig4s1){ref-type="fig"}).

*I~NaP~*-blockers or a KCC2-enhancer normalize the excitability of the spinal cord after SCI {#s2-6}
--------------------------------------------------------------------------------------------

We examined whether the SCI-induced spinal cord hyperexcitability in vitro can be reduced when persistent inward currents or KCC2 are targeted. Riluzole below 10 µM depresses *I*~NaP~ in lumbar motoneurons without altering glutamatergic transmission ([@bib68]). Bath-applied riluzole (5 µM) normalized the excitability of the SCI spinal cord. The SLR was decreased and the LLR was abolished without affecting the monosynaptic reflex (p\<0.05, p\<0.01 and p\>0.05, respectively; [Figure 5A--C](#fig5){ref-type="fig"}). In addition, spontaneous bursting activity was markedly reduced (p\<0.01; [Figure 5D--E](#fig5){ref-type="fig"}). Similar results were obtained for dorsal root-evoked (p\<0.05; [Figure 5F--H](#fig5){ref-type="fig"}) or spontaneous bursting (p\<0.001; [Figure 5I--J](#fig5){ref-type="fig"}) motor outputs when the Nav1.6-mediated current was specifically blocked by 4,9-anhydro-tetrodotoxin (200 nM; 4,9-ah-TTX ([@bib62]). Conversely, the selective pharmacological enhancement of *I*~NaP~ with 100 nM of the steroidal alkaloid veratridine ([@bib3]; [@bib68]) triggered LLR (p\<0.01; [Figure 5---figure supplement 1A--C](#fig5s1){ref-type="fig"}) and increased spontaneous bursting activity (p\<0.05; [Figure 5---figure supplement 1D--E](#fig5s1){ref-type="fig"}). The veratridine-induced motor responses were occluded by riluzole (5 µM, [Figure 5---figure supplement 1A--C](#fig5s1){ref-type="fig"}). Blockade of the second persistent inward current '*I*~CaP~' by the L-type Ca^2+^ channel blocker nifedipine (20 µM) did not reduce either hyperreflexia or spontaneous bursting activity (p\>0.05; [Figure 5---figure supplement 2A--E](#fig5s2){ref-type="fig"}). However, the L-type Ca^2+^ channel enhancer Bay-K (10 µM) triggered LLR and spontaneous bursting activity in isolated spinal cord from control intact neonatal rats (p\<0.05; [Figure 5---figure supplement 2F--J](#fig5s2){ref-type="fig"}). The role of KCC2 in SCI-induced hyperexcitability was explored with the KCC2 activator, prochlorperazine (PCPz) ([@bib49]). PCPz used at the minimal concentration (10 µM) to restore KCC2 function after SCI ([@bib49]), reduced the LLR and spontaneous bursting activity in amplitude and frequency (p\<0.01, p\<0.01 and p\<0.05 respectively; [Figure 5K--O](#fig5){ref-type="fig"}) with no effects on SLR or monosynaptic reflex amplitude.

![*I~NaP~*-blockers or a KCC2-enhancer normalize the excitability of the spinal cord below SCI.\
(**A,D,F,I,K,N**) Representative L5 ventral root activities (VR L5) evoked by a supramaximal stimulation (St.) of the ipsilateral dorsal root (**A,F,K**) or occurring spontaneously (**D,I,N**) in spinal cords isolated from SCI rats (4--5 d post-SCI) before (black) and after bath-applying 5 µM riluzole (**A,D**); red, 30 min, *n* = 8 rats), 200 nM 4,9-ah-TTX (**F,I**; blue, 30 min, *n* = 15 rats for **F**, n = 20 rats for **I**) or 10 µM PCPz (**K,N**; green, 30 min, *n* = 9 rats for **K**, n = 11 rats for N). Insets in (**A,F,K**) illustrate enlargements of the monosynaptic response. (**B,G,L**) Average peristimulus time histogram (PSTH, bin width: 20 ms) of dorsal root evoked L5 ventral root responses before (black) and after (color) bath-applying the above-mentioned drugs. (**C,E,H,J,M,O**) Group means quantification of: the monosynaptic reflex and events per rat detected over time windows of 10--40 ms and 500--15,000 ms post-stimulus for SLR and LLR, respectively (**C,H,M**), and spontaneous activities (**E,J,O**). \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, comparing data collected before and after adding drugs mentioned above; Wilcoxon paired test. Data are mean ± SD. Underlying numerical values can be found in the [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}.\
Figure 5---source data 1.Values displayed in bar plots shown in [Figure 5C, E, H, J, M, O](#fig5){ref-type="fig"}.](elife-51404-fig5){#fig5}

The SCI-induced alteration of *I*~NaP~ and *E*~IPSP~ promotes spinal hyperexcitability {#s2-7}
--------------------------------------------------------------------------------------

The combination of up- and down-regulation of *I*~NaP~ and *E*~IPSP~ by calpain might be critically involved in spinal hyperexcitability. To study a possible synergistic effect between *I*~NaP~ and *E*~IPSP~ in increasing the excitability of the spinal cord after SCI, we pharmacologically mimicked the SCI-induced alteration of *I*~NaP~ and *E*~IPSP~ in spinal cords isolated from control intact neonatal rats. With a concentration of 60 nM, veratridine mimicked the I~NaP~ increase caused by SCI ([@bib15]) (see also Figure 6 in [@bib68]). A dose of 30 µM KCC2 antagonist, DIOA, can also reproduce the \~10 mV depolarizing shift of E~IPSP~ reported in motoneurons after SCI ([@bib38]; see also Figure 4 in [@bib11]). At these concentrations, neither veratridine nor DIOA alone triggered either hyperreflexia or an increase in spontaneous bursts (gray, p\>0.05; [Figure 6A--F](#fig6){ref-type="fig"}). However, when veratridine and DIOA were co-applied, enhanced LLR and spontaneous bursts were triggered (red, [Figure 6A--H](#fig6){ref-type="fig"}).

![*E*~IPSP~ and *I*~NaP~ act synergistically to promote spinal hyperexcitability.\
(**A**) Representative L5 ventral root activities (VR L5) evoked by a supramaximal stimulation (St.) of the ipsilateral dorsal root in spinal cords isolated from intact rats (4--5 d old, n = 11 rats) before (black) and after (gray) the application of veratridine (60 nM, 30 min) followed by the superfusion (red) of DIOA (30 µM, 30 min). (**D**) Same experiments (n = 6 rats) as in (**A**) but by applying DIOA (gray) before veratridine (red). (**B,E**) Average peristimulus time histogram (PSTH, bin width: 20 ms) of dorsal root evoked L5 ventral root responses recorded either in the presence of veratridine or DIOA alone (gray), or in the presence of both (red). (**C,F**) Group means quantification of events per rat detected over time windows of 10--40 ms and 500--15,000 ms post-stimulus for SLR and LLR, respectively. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 repeated measures one-way ANOVA. (**G**) Representative spontaneous activities recorded on L5 ventral root (VR L5) in spinal cords isolated from intact rats (4--5 d old, n = 19 rats) before (black) and after (red) the superfusion of 60 nM veratridine with 30 µM DIOA (30 min). (**H**) Group means quantification of spontaneous activities. \*\*p\<0.01, \*\*\*p\<0.001 Wilcoxon paired test. Data are mean ± SD. Underlying numerical values can be found in the [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}.\
Figure 6---source data 1.Values displayed in bar plots shown in [Figure 6C, F, H](#fig6){ref-type="fig"}.](elife-51404-fig6){#fig6}

Discussion {#s3}
==========

Numerous studies on adult animal models delineate the hyperexcitable state of motoneurons as one of the causes of spasticity, presumably because of an increase of *I*~NaP~ and a decrease of KCC2 expression. The present study performed in neonatal rats identifies the activation of calpains as the upstream mechanism of the hyperexcitability of motoneurons after SCI. Calpain-mediated cleavage of Nav channels and KCC2 up- and down-regulates *I*~NaP~ and inhibition, respectively, in lumbar motoneurons. The reduction of calpain activity normalizes *I*~NaP~ and the strength of inhibitory transmission, and thereby alleviates spasticity. Altogether, these findings uncover a new cellular mechanism contributing to spasticity and provide novel therapeutic targets. Rather than targeting Nav channels or KCC2 independently, inhibition of calpains appears as a promising therapy by targeting two pathways that are crucial for the development of spasticity, 'killing two birds with one stone'.

The main spasticity symptoms develop within one week following SCI in neonatal rats, and correlate with an early appearance of hyperexcitability in the spinal cord. The emergence of spasticity is surprisingly faster than that of adult animals, which appears several weeks after the injury. A more active calpain-mediated proteolysis during early development may explain this age-dependent discrepancy. Indeed, calpain proteolysis is necessary for the pruning of axons during development ([@bib80]) and the natural calpain inhibitory peptide, calpastatin, increases slowly in the CNS during the first weeks of life ([@bib47]). The lower presence of this inhibitor in newborn rats may explain why hyperexcitability after a neonatal SCI developed faster. Also at birth, rat motoneurons overexpress NMDA receptors ([@bib75]) which have been demonstrated to be efficient in activating calpains in pathological conditions ([@bib82]). In sum, the low expression of calpastatin combined with a high expression of NMDA receptors may contribute to a fast increase of motoneuronal excitability after a SCI in newborn rats.

This hyperexcitability emerges in vitro in the form of high-frequency spontaneous bursting activity and enhanced, prolonged sensory-evoked LLR. We provided evidence that both are dependent on *I*~NaP~ and KCC2 dysfunction. *I*~NaP~ plays an important role in the operation of the spinal locomotor network ([@bib67]; [@bib68]; [@bib13]; [@bib10]; [@bib14]) and its increase after SCI promotes prolonged plateau potential firing in motoneurons and hyperreflexia, both in animal models and humans ([@bib48]; [@bib46]; [@bib43]; [@bib69]). Supersensitivity of motoneurons to residual serotonin after SCI leads to the facilitation of *I*~NaP~ ([@bib32]; [@bib33]). Here, we demonstrate that calpain-dependent cleavage of Nav channels also upregulates *I*~NaP~ in lumbar motoneurons. If serotonin recruits calpains after SCI, similarly to what observed in *Aplysia* motoneurons ([@bib9]), remains to be tested.

The exact mechanisms involved in the facilitation of *I*~NaP~ by calpain are not fully understood. As previously observed after a traumatic brain injury ([@bib76]), proteolyzed Nav channels remain in the plasma membrane and thus might interfere with biophysical properties of full-length voltage-gated channels ([@bib53]). On the other hand, some determinants governing the inactivation of Nav channels are sensitive to proteases, which can increase *I*~NaP~ ([@bib4]; [@bib27]; [@bib20]). Whatever the mechanisms, a clear relationship is given by our previous study in which calpain-mediated cleavage of Nav1.6 channels in HEK-293 cells up-regulates *I*~NaP~ ([@bib15]). Because Nav1.6 channels are highly expressed in spinal motoneurons ([@bib2]; [@bib25]; [@bib15]), their cleavage likely contributes to increase *I*~NaP~ after SCI. This is consistent with our result that pharmacological inhibition of Nav1.6 channels significantly reduced hyperexcitability after SCI. Further support comes from mutation of Nav1.6 channels that leads to severe myoclonic spasms with a fivefold increase of *I*~NaP~ ([@bib73]). It is noteworthy that the rescue of *I*~NaP~ by MDL28170 is only partial. Although an incomplete block of calpains by MDL28170 cannot be excluded, calpain-independent mechanism(s) may contribute to increase *I*~NaP~. Since the activation of 5HT~2~ receptors facilitates *I*~NaP~ ([@bib33]), the constitutive activation of 5HT~2~ receptors after SCI ([@bib55]) might be one of them. Also, the amount of full-length Nav channels (\~250 kDa) at the plasma membrane never changed after either the post-SCI activation of calpains ([@bib15]) or their inhibition by a MDL28170 treatment (see [Figure 3F](#fig3){ref-type="fig"}). As a compensation mechanism depending on the number of proteolytic fragments, it is possible that the translocation of fragments into the nucleus maintains constant the expression level of the full-length channel at the membrane by regulating the Nav channel transcription ([@bib58]).

Synaptic disinhibition of motoneurons after SCI also contributes to spasticity and results from a decreased expression of KCC2 ([@bib11]). Although a down-regulation of KCC2 has been described after SCI ([@bib11]; [@bib22]; [@bib54]; [@bib18]; [@bib19]), the causal molecular mechanisms remain unknown. Here, we provide evidence that activation of calpains is one of the molecular basis for disinhibition of motoneurons after SCI. A direct relationship between calpain and KCC2 is given by our studies on spinal cord homogenates, in which exogenous application of active calpains reduces KCC2 in its oligo and monomeric forms. The sensitivity of KCC2 to calpain is consistent with the presence of two predicted sites (PEST motifs) for cleavage by calpain within the C-terminal domain ([@bib52]; [@bib1]). Since the ability of KCC2 to extrude Cl^-^ requires the C-terminal domain ([@bib52]; [@bib1]) and that the KCC2 antibody targets the C-tail, its cleavage by calpains after SCI likely accounts for both the immunostaining decrease of KCC2 at the plasma membrane and the loss of chloride extrusion resulting in the depolarizing shift of *E*~IPSP~ in motoneurons ([@bib11]). The tight relationship between the calpain-mediated proteolysis of KCC2 and the altered Cl^-^ homeostasis is supported by our observation that an acute inhibition of calpains by MDL28170 rapidly restores both *E*~IPSP~ and KCC2. The rapid rescue of KCC2 by the acute application of MDL28170 is in agreement with the fast pharmacodynamic of MDL28170 to cross the brain blood barrier ([@bib51]) and the extremely high rate (minutes) in KCC2 turnover at the plasma membrane ([@bib45]). Regarding the rescue of KCC2 by MDL28170, oligomers appear more sensitive to calpains than monomers after SCI. As phosphorylation regulates the vulnerability of substrates to calpains ([@bib64]), the post-SCI dephosphorylation of KCC2 at the serine 960 ([@bib54]), in the vicinity of PEST motifs, might contribute to sensitize more oligomers to calpains.

Our results suggest that KCC2 and *I*~NaP~ appear to cooperate in promoting spinal hyperexcitability after SCI. In line with this, a modeling investigation demonstrated that the depolarizing shift of E~IPSP~ after SCI facilitates the recruitment of persistent inward currents in motoneurons ([@bib74]). The depolarizing shift of *E*~IPSP~ after a decrease in KCC2 may enable the unusual long-lasting depolarization reported in motoneurons after SCI ([@bib46]), which is required to recruit *I*~NaP~. In turn, *I*~NaP~ will promote plateau potentials resulting in self-sustaining spiking in motoneurons ([@bib48]; [@bib10]) that drives spasticity ([@bib7]; [@bib28]; [@bib46]). Furthermore, termination of plateau potentials by hyperpolarizing the motoneuron ([@bib34]) will be much more difficult in a context of disinhibition; this may explain the fasciculation-like contractions commonly recorded in spastic subjects ([@bib28]; [@bib79]; [@bib83]). Therefore, *I*~NaP~-blockers such as riluzole, or KCC2 enhancers likely alleviate spasticity ([@bib15]; [@bib49]) by decoupling the tandem response driven by enhanced *I*~NaP~ and decreased KCC2. The riluzole is currently approved for humans affected by Amyotrophic Lateral Sclerosis (ALS). Our data provide strong preclinical evidence for translation to chronic SCI subjects, a process that will likely be facilitated by clinical trials that are currently in progress to test the neuroprotective effects of riluzole in the acute phase of SCI ([@bib30]).

We identify calpain as the upstream mechanism responsible for the hyperexcitability of motoneurons after SCI. Calpains exist in the CNS mainly as two major isoforms, µ-calpain (calpain-I) and m-calpain (calpain-II) that differ on the range of \[Ca^2+^\] required for their activation (µM and mM, respectively). As previously observed in adult rodents ([@bib65]; [@bib24]; [@bib63]; [@bib81]), we found that the expression of calpain-I increases after SCI in neonatal rats. However, the protease protein expression does not necessarily correspond to enzyme's catalytic activity. Furthermore, calpain-I and -II may have opposite functions. After a traumatic brain injury (TBI), calpain-I and -II appear neuroprotective and neurodegenerative, respectively ([@bib5]). Therefore, the respective contribution of calpain-I and -II in the hyperexcitability of motoneurons after SCI remains to be clarified.

Calpain-mediated changes in motoneurons alone are unlikely to account for all the post-injury spinal hyperexcitability. Premotor excitatory interneurons, including locomotor network-related interneurons, may play a critical role in initiating muscle spasm activity ([@bib36]; [@bib6]; [@bib50]). In line with this, we found that most sensory-evoked LLRs are composed of a fictive locomotor episode, suggesting enhanced sensory recruitment of the locomotor central pattern generator (CPG). This leads us to believe that part of muscle spasm, and especially clonus (involuntary rhythmic contractions), might be a manifestation of a hyperexcitable locomotor CPG. Enhanced sensory-evoked LLR has been previously described in the sacrocaudal spinal cord from adult SCI rodents but differs in some aspects from our results with neonatal lumbar motoneurons. Indeed, *I*~CaP~ contributes to sacrocaudal hyperreflexia by promoting plateaus in motoneurons ([@bib48]; [@bib46]) while disinhibition appears negligible ([@bib6]). The *I*~CaP~ appears to have a negligible role in lumbar hyperreflexia from neonatal SCI rats, in line with previous work showing a full maturation of L-type Ca^2+^ channels at second/third post-natal weeks ([@bib39]). However, we also demonstrate that some of these channels are already expressed in the first post-natal week, as their pharmacological activation by Bay-K triggered LLRs. Thus, it is likely that the contribution of L-type Ca^2+^ channels to the LLR increases with age. Alternatively, temperature and ionic composition of the extracellular medium may account for the relative contribution of *I*~NaP~ and *I*~CaP~ in generating LLRs. In vitro studies in adults were performed at room temperature with high extracellular \[Ca^2+^\] (≥2.5 mM) ([@bib48]; [@bib46]; [@bib6]), far from physiological conditions \[body temperature 37°C; 1.2 mM of Ca^2+^ in the CSF ([@bib56]; [@bib40]; [@bib14]). As a consequence, Ca^2+^ currents are potentiated ([@bib16]; [@bib17]), *I*~NaP~ is reduced ([@bib68]) and thermosensitive *I*~NaP-~dependent plateaus in motoneurons are dampened down ([@bib10]). Also, the disinhibition seen in the SCI lumbar enlargement, linked to the decrease of KCC2 ([@bib11]), seems unimportant in the sacrocaudal spinal cord ([@bib6]). Diversity of KCC2 expression between motoneurons innervating distinct muscles ([@bib72]) or variation in the sacral inhibitory circuitry ([@bib37]) may account for this discrepancy. Spinal cord level-specific differences in neuronal responses to SCI are probable with respect to the special anatomy and function of the sacrocaudal spinal cord ([@bib60]; [@bib61]).

To conclude, our study sheds light on the etiology of spasticity and opens novel perspectives to develop therapies by targeting calpains. The discovery of calpain as a new upstream mechanism leading to spasticity, is of special importance given the lack of translational results obtained from previously tested therapeutic approaches. Since spinal maladaptive mechanisms triggered by calpain start taking place within the first hours after injury in our SCI model, it is conceivable that early therapies against calpain might show a higher effectiveness. Because altered chloride homeostasis and proteolysis of Nav channels have been implicated in other neurological disorders such as traumatic brain injury for which calpains are recruited ([@bib41]; [@bib76]; [@bib78]), the involvement of calpains might be broadened to other pathologies leading to an excitatory/inhibitory imbalance.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                   Designation                                              Source or\                     Identifiers                                                                                 Additional\
  (species) or\                                                                                            reference                                                                                                                  information
  resource                                                                                                                                                                                                                            
  ----------------------------------------------- -------------------------------------------------------- ------------------------------ ------------------------------------------------------------------------------------------- ----------------
  Antibody                                        mouse monoclonal anti-PanNav                             Sigma                          clone K58/35\                                                                               (1:500)
                                                                                                                                          CAT\#S8809\                                                                                 
                                                                                                                                          RRID:[AB_477552](https://scicrunch.org/resolver/AB_477552)                                  

  Antibody                                        rabbit polyclonal anti-Na~v~1.6                          Alomone                        Cat \# ASC-009\                                                                             (1:200)
                                                                                                                                          RRID:[AB_2040202](https://scicrunch.org/resolver/AB_2040202)                                

  Antibody                                        rabbit polyclonal anti-KCC2                              Millipore                      CAT\# 07--432\                                                                              (1:400, 1:500)
                                                                                                                                          RRID:[AB_310611](https://scicrunch.org/resolver/AB_310611)                                  

  Antibody                                        rabbit polyclonal anti-calpain-I                         Ozyme                          CAT\#2556S                                                                                  (1:500)

  Antibody                                        rabbit polyclonal anti-calpain-II                        Millipore                      CAT\#AB81023\                                                                               (1:500)
                                                                                                                                          RRID:[AB_1586917](https://scicrunch.org/resolver/AB_1586917)                                

  Antibody                                        ImmunoPure goat HRP-conjugated mouse-specific antibody   Thermo Fisher Scientific       CAT\#0031430\                                                                               (1:40000)
                                                                                                                                          RRID:[AB_228307](https://scicrunch.org/resolver/AB_228307)                                  

  Antibody                                        AlexaFluor-488 goat anti-mouse IgG2b                     Thermo Fisher Scientific       CAT\# A-21141\                                                                              (1:800)
                                                                                                                                          RRID:[AB_141626](https://scicrunch.org/resolver/AB_141626)                                  

  Antibody                                        AlexaFluor-546 F(ab')two goat anti-rabbit IgG            Thermo Fisher Scientific       CAT\# A-11071\                                                                              (1:400)
                                                                                                                                          RRID:[AB_2534115](https://scicrunch.org/resolver/AB_2534115)                                

  Chemical compound, drug                         NaCl                                                     Sigma-Aldrich                  CAT\# 71376                                                                                 

  Chemical compound, drug                         KCl                                                      Sigma-Aldrich                  CAT\# P3911                                                                                 

  Chemical compound, drug                         NaH~2~PO~4~                                              Sigma-Aldrich                  CAT\# S0751                                                                                 

  Chemical compound, drug                         MgSO~4~                                                  Sigma-Aldrich                  CAT\# 1880                                                                                  

  Chemical compound, drug                         CaCl~2~                                                  Sigma-Aldrich                  CAT\# 21115                                                                                 

  Chemical compound, drug                         NaHCO~3~                                                 Sigma-Aldrich                  CAT\# S6014                                                                                 

  Chemical compound, drug                         D-glucose                                                Sigma-Aldrich                  CAT\# G8270                                                                                 

  Chemical compound, drug                         K^+^-gluconate                                           Sigma-Aldrich                  CAT\# P1847                                                                                 

  Chemical compound, drug                         MgCl~2~                                                  Sigma-Aldrich                  CAT\# M8266                                                                                 

  Chemical compound, drug                         HEPES                                                    Sigma-Aldrich                  CAT\# H3375                                                                                 

  Chemical compound, drug                         EGTA                                                     Sigma-Aldrich                  CAT\# E3889                                                                                 

  Chemical compound, drug                         ATP                                                      Sigma-Aldrich                  CAT\# A9062                                                                                 

  Chemical compound, drug                         GTP                                                      Sigma-Aldrich                  CAT\# G9002                                                                                 

  Chemical compound, drug                         Sucrose                                                  Sigma-Aldrich                  CAT\# S9378                                                                                 

  Chemical compound, drug                         Cadmium Chloride                                         Sigma-Aldrich                  CAT\# 202908                                                                                

  Chemical compound, drug                         Tetraethylammonium chloride                              Sigma-Aldrich                  CAT\# 86616                                                                                 

  Chemical compound, drug                         Nifedipine                                               Sigma-Aldrich                  CAT\# N7634                                                                                 

  Chemical compound, drug                         Dimethylsulphoxide                                       Sigma-Aldrich                  CAT\# D8418                                                                                 

  Chemical compound, drug                         Paraformaldehyde                                         EMS                            CAT\# 15714 s                                                                               

  Chemical compound, drug                         Phosphate Buffered Saline                                Argene Biomérieux              CAT\# 33--011                                                                               

  Chemical compound, drug                         Tissue-Tek OCT compound                                  VWR                            CAT\# 25608--930                                                                            

  Chemical compound, drug                         Tris-buffered saline                                     Bio-world                      CAT\# 105300272                                                                             

  Chemical compound, drug                         Triton X-100                                             Sigma-Aldrich                  CAT\# T9284                                                                                 

  Chemical compound, drug                         CompleteMini                                             Roche diagnostic Basel         CAT\#11836170001                                                                            

  Chemical compound, drug                         Iodoacetamide                                            Sigma-Aldrich                  CAT\#I1149                                                                                  

  Chemical compound, drug                         Igepal CA-630                                            Sigma-Aldrich                  CAT\#I8896                                                                                  

  Chemical compound, drug                         SDS                                                      Sigma-Aldrich                  CAT\#05030--1 L-F                                                                           

  chemical compound, drug                         Acryl/Bisacrylamide solution                             Biorad                         CAT\#161--0146                                                                              

  Chemical compound, drug                         PMSF                                                     Sigma-Aldrich                  CAT\#93482                                                                                  

  Chemical compound, drug                         Pepstatin A                                              Sigma-Aldrich                  CAT\#77170                                                                                  

  Chemical compound,\                             MDL28170                                                 Calbiochem                     CAT\#208722                                                                                 
  drug                                                                                                                                                                                                                                

  Chemical compound, drug                         Calpain 1                                                Calbiochem                     CAT\#208712                                                                                 

  Chemical\                                       Bay K8644                                                Sigma-Aldrich                  CAT\# [B112](https://www.sigmaaldrich.com/catalog/product/sigma/b112?lang=fr&region=FR)     
  compound,\                                                                                                                                                                                                                          
  drug                                                                                                                                                                                                                                

  chemical\                                       CNQX                                                     Sigma-Aldrich                  CAT\# [C127](https://www.sigmaaldrich.com/catalog/product/sigma/c127?lang=fr&region=FR)     
  compound,\                                                                                                                                                                                                                          
  drug                                                                                                                                                                                                                                

  Chemical\                                       DIOA                                                     Sigma-Aldrich                  CAT\# [D129](https://www.sigmaaldrich.com/catalog/product/sigma/d129?lang=fr&region=FR)     
  compound,\                                                                                                                                                                                                                          
  drug                                                                                                                                                                                                                                

  Chemical compound, drug                         Veratridine                                              Sigma-Aldrich                  CAT\# [V5754](https://www.sigmaaldrich.com/catalog/product/sigma/v5754?lang=fr&region=FR)   

  Chemical compound,\                             AP5                                                      Tocris                         CAT\# 3693/10                                                                               
  drug                                                                                                                                                                                                                                

  Chemical compound,\                             PCPz                                                     Tocris                         CAT\# 3287/100                                                                              
  drug                                                                                                                                                                                                                                

  Chemical\                                       Riluzole                                                 Tocris                         CAT\# 0768/25                                                                               
  compound,\                                                                                                                                                                                                                          
  drug                                                                                                                                                                                                                                

  Chemical compound, drug                         4,9-ah-TTX                                               Focus Biomolecules             CAT\# 10--3700                                                                              

  Strain, strain background (Rattus norvegicus)   Wistar rats                                              Charles River Laboratories     RRID:[RGD_2308816](https://scicrunch.org/resolver/RGD_2308816)                              

  Software, algorithm                             pClamp v10.3                                             Molecular Devices              RRID:[SCR_011323](https://scicrunch.org/resolver/SCR_011323)                                

  Software, algorithm                             ImageJ v1.50i                                            <https://imagej.nih.gov/ij/>   RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)                                

  Software, algorithm                             FluoView v5.0                                            Olympus                        RRID:[SCR_014215](https://scicrunch.org/resolver/SCR_014215)                                

  Software, algorithm                             Image Lab v5.1                                           Bio-Rad                        RRID:[SCR_014210](https://scicrunch.org/resolver/SCR_014210)                                

  Software, algorithm                             Graphpad Prism                                           Prism                          RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)                                

  Other                                           Vibrating microtome                                      Leica                          VT1000S\                                                                                    
                                                                                                                                          RRID:[SCR_016495](https://scicrunch.org/resolver/SCR_016495)                                

  Other                                           Temperature controller                                   Warner Instruments             CL-100                                                                                      

  Other                                           Nikon Eclipse microscope                                 Nikon                          E600FN                                                                                      

  Other                                           Confocal microscope                                      Zeiss                          LSM510                                                                                      

  Other                                           Infrared-sensitive CCD camera                            Hitachi                        KP-200/201                                                                                  

  Other                                           Digidata 1440a interface                                 Molecular Devices              N/A                                                                                         

  Other                                           Multiclamp 700B amplifier                                Molecular Devices              N/A                                                                                         

  Other                                           Borosilicate glass capillaries                           World Precision Instruments    CAT\# TW150-4                                                                               

  Other                                           Sutter P-97 puller                                       Sutter Instruments             RRID:[SCR_016842](https://scicrunch.org/resolver/SCR_016842)                                

  Other                                           Knittel Glass coverslips                                 Dutscher                       CAT\# 900529                                                                                

  Other                                           Polysine slides                                          Thermoscientific               CAT\# P4981                                                                                 

  Other                                           Small Animal Ventilator                                  CWE                            SAR-830/AP                                                                                  

  Other                                           Cardiotachometer                                         CWE                            CT-1000                                                                                     

  Other                                           Chemidoc imaging system XRS+                             Bio-rad                        RRID:[SCR_014210](https://scicrunch.org/resolver/SCR_014210)                                
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Ethics statement {#s4-1}
----------------

We made all efforts to minimize animal suffering and the number of animals used. All animal care and use conformed to the French regulations (Décret 2010--118) and were approved by the local ethics committee (Comité d'Ethique en Neurosciences INT-Marseille, CE Nb A1301404, authorization Nb 2018110819197361).

Surgery and postoperative care {#s4-2}
------------------------------

The spinal cord trans-section was performed in neonatal rats within the first 12 hr after birth. Animals were anesthetized by hypothermia. After a midline skin incision, a laminectomy was performed to expose lower thoracic segments of the spinal cord. The dura was opened and the spinal cord was completely transected at the T8-T9 segmental level. The lesion cavity was filled with sterile absorbable local hemostat Surgicoll. Finally, the wound was covered with Steri-Strips (3M Health Care, St. Paul, MN) and animals were kept warm and wet for 2 hr in cotton-wool swab impregnated with their mother smell before they returned to their home cage with their mother. The antibiotic amoxycilin (150 mg/kg, s.c.) was subcutaneously applied at the incision site just before suturing the skin to prevent bacterial infections. Note that only one-shot topical amoxycilin was administered to limit the potential emergence of antibiotic-resistant bacterial strains. Sham animals were submitted to all procedures except the spinal cord transection.

Assessment of spastic motor behaviors {#s4-3}
-------------------------------------

Animals were tested 4--5 days after SCI, when signs of spastic motor behaviors were visible such as excessive involuntary twitch/movement, exaggeration of reflexes\... *For behavioral assessment* of spastic behaviors pups were removed from their home cage, weighted, and placed on a heating pad thermo-controlled at \~34.5 ± 1°C. Dorsal view of the animals were recorded with a digital video camera. Recordings began 10 min after pups had been placed on the heating pad so as to ensure that pups were thermally stable. Then, a continuous 10 min recording was acquired after which time pups were returned to their home cages. The number of myoclonic twitching of the hindlimbs and the tail was scored in a single pass through the video record. *For the electrophysiological assessment* of spasticity, a stainless steel needle electrode was inserted transcutaneously into the triceps surae muscles (ankle extensors), and the reference electrode was placed subcutaneously on the back. Animals were slightly anesthetized by hypothermia before inserting electrodes. After a 20 min acclimation period, motor responses to pinch tail between the thumb and the index finger were recorded. EMG signals were amplified (100x) and bandpass filtered (300 Hz to 5 kHz; A-M Systems Amplifier, Everett, WA; model 1700) before sampling at 13.5 kHz (Digidata 1440A, Molecular Devices). The pressure manually applied to the last third of the tail was of increasing intensity until the appearance of a motor response in hindlimbs. The pressure (weight in grams) was recorded by a miniature pressure sensor placed between the thumb and the tail and monitored on line. Experimenters were not blinded during the whole procedure, as signs of spasticity were evident in SCI pups. However, experimenters were blind for the data analysis of electrophysiological experiments.

In vitro preparations {#s4-4}
---------------------

Details of the in vitro preparations have been previously described ([@bib12]) and are only summarized here. *For the whole spinal cord preparation,* the spinal cord and ventral roots were removed from sacral segments up to T~8~--T~10~. The spinal cord was pinned down, ventral side up, in the recording chamber. All dissection and recording procedures were performed under continuous perfusion with aCSF composed of (in mM): 120 NaCl, 4 KCl, 1.25 NaH~2~PO~4~, 1.3 MgSO~4~, 1.2 CaCl~2~, 25 NaHCO~3~, 20 D-glucose, pH 7.4 (32--34°C). *For the slice preparation*, the lumbar spinal cords was isolated in ice-cold (\<4°C) artificial cerebrospinal fluid (aCSF) solution with the following composition (in mM): 232 sucrose, 3 KCl, 1.25 KH~2~PO~4~, 4 MgSO~4~, 0.2 CaCl~2~, 26 NaHCO~3~, 25 D-glucose, pH 7.4. The lumbar spinal cord was then introduced into a 1% agar solution, quickly cooled, mounted in a vibrating microtome (Leica VT1000S) and sliced (350 µm) through the L4-5 lumbar segments. Slices were immediately transferred into the holding chamber filled with aCSF composed of (in mM): 120 NaCl, 3 KCl, 1.25 NaH~2~PO~4~, 1.3 MgSO~4~, 1.2 CaCl~2~, 25 NaHCO~3~, 20 D-glucose, pH 7.4 (32--34°C). Following a 1 hr resting period, individual slices were transferred to a recording chamber that was continuously perfused with the same medium heated to \~32°C. All solutions were oxygenated with 95% O~2~/5% CO~2~.

In vitro recordings and stimulation {#s4-5}
-----------------------------------

*For the whole spinal cord preparation*, motor outputs were recorded using extracellular stainless steel electrodes placed in contact with right and left lumbar ventral roots (L5) and insulated with Vaseline. The ventral root recordings were amplified (×2,000), high-pass filtered at 70 Hz, low-pass filtered at 3 kHz, and sampled at 10 kHz. Custom-built amplifiers enabled simultaneous online rectification and integration (100 ms time constant) of raw signals. Monopolar stainless steel electrodes were also placed in contact with the dorsal roots and insulated with Vaseline to deliver a brief supramaximal stimulation (0.2 ms duration). Glass suction electrodes were sometimes used to stimulate the ventral funiculus at the L~2~--L~3~ level. After the pia had been removed, lumbar motoneurons were recorded intracellularly using glass microelectrodes filled with 2 M K-acetate (90--150 MΩ resistance). Intracellular potentials were recorded in the discontinuous current-clamp (DCC) mode (Axoclamp 2B amplifier; Digidata 1200 interface). Only neurons exhibiting a stable (\>15 min) resting membrane potential were considered for analysis. Motoneurons were identified by the antidromic response to stimulation of the ventral roots. Stimulation of the ventral funiculus usually induced inhibitory postsynaptic potentials (IPSPs) in the presence of 2-amino-5-phosphonovaleric acid (AP5, 30--100 μM) and 6-cyano-7-nitroquin-oxaline-2,3-dione (CNQX, 3--10 μM). IPSPs were recorded at various holding potentials (500 ms-long current pulses). *For the slice preparation,* whole-cell patch-clamp recordings were performed in voltage-clamp mode from motoneurons located in the lateral ventral horn using a Multiclamp 700B amplifier (Molecular Devices). Motoneurons were visually identified with video microscopy (Nikon Eclipse E600FN) coupled to infrared differential interference contrast, as the largest cells located in layer IX. Only neurons with a membrane capacitance higher than 100 pF were considered. The image was enhanced with a Hitachi KP-200/201 infrared-sensitive CCD camera and displayed on a video monitor. Patch electrodes (2--4 MΩ) were pulled from borosilicate glass capillaries (1.5 mm OD, 1.12 mm ID; World Precision Instruments) on a Sutter P-97 puller (Sutter Instruments Company) and filled with intracellular solution containing (in mM): 140 K^+^-gluconate, 5 NaCl, 2 MgCl~2~, 10 HEPES, 0.5 EGTA, 2 ATP, 0.4 GTP, pH 7.3 (280 to 290 mOsm). Pipette and neuronal capacitive currents were canceled and, after breakthrough, the series resistance was compensated and monitored. Recordings were digitized on-line and filtered at 10 kHz (Digidata 1322A, Molecular Devices). The main characterization of I~NaP~ was accomplished by slow ramp increase from −70 mV to −10 mV, slow enough (12 mV/s) to prevent transient sodium channel opening.

Immunohistochemistry {#s4-6}
--------------------

Spinal cords were immersion-fixed for 1 hr in 0.25% PFA, washed in PBS and cryoprotected overnight at 4°C in 20% sucrose in PBS. Lumbar spinal cords (L4-L5) were then frozen in OCT medium (Tissue Tec), cryosectioned (20 µm) and processed for immunohistochemistry. Sections from the control vs. SCI rats were mounted on the same slides and processed simultaneously. Slices were then (i) rehydrated in PBS at room temperature (15 min), (ii) permeated with 1% Bovin Serum Albumin (BSA), 2% Natural Goat Serum (NGS) and 0.2% Triton x-100 (1 hr), (iii) incubated overnight at 4°C in the following affinity-purified rabbit Na~v~1.6 (residues 1042--1061; 1:200; ASC009, Alomone) specific polyclonal antibodies, KCC2 (residues 932--1043; 1:400, 07--432, Millipore) (iv) washed in PBS (3 × 5 min), (v) incubated with fluorescent-conjugated secondary antibodies \[Alexa 488- or 546-conjugated rabbit-specific antibodies (1:800 and 1:400; Lifetechnologies Carlsbad CA USA) used for visualization of the rabbit polyclonal antibodies\] in a solution containing 1% BSA and 2% NGS (1.5 hr), (vi) washed in PBS 3 × 5 min, (vii) coverslipped with a gelatinous aqueous medium. In control experiments, the primary antiserum was either omitted or replaced with rabbit immunoglobulin fraction during the staining protocol. Sections were scanned using a laser scanning confocal microscope (Zeiss LSM510) in stacks of 1μm-thick optical sections at ×20 magnification and processed with the Fluoview software. Each optical section resulted from two scanning averages. We used identical settings, finely tuned to avoid saturation, for the whole series. Each figure corresponds to a projection image from a stack of optical sections.

Membrane protein isolation and western blots {#s4-7}
--------------------------------------------

Tissues were collected from spinal cord lumbar enlargements and frozen after removing the dorsal and ventral roots. For the membrane fraction, corresponding to the plasma membrane-enriched fraction, samples were homogenized in ice-cold lysis buffer (320 mM sucrose, 5 mM Tris-HCL pH 7.5, 10 µM iodoacetamide) supplemented with protease inhibitors (CompleteMini, Roche diagnostic Basel, Switzerland). Unsolubilized material was pelleted by centrifugation at 7,000 g for 5 min. The supernatant was subjected to an additional centrifugation step at 18000 g for 70 min at 4°C. Pellets were collected and homogenized in ice cold lysis buffer (1% Igepal CA-630, Phosphate Buffer Saline 1X, 0.1% SDS, 10 µM iodoacetamide), supplemented with protease inhibitors (CompleteMini, Roche diagnostic). Protein concentrations were determined using a detergent-compatible protein assay (Bio-Rad, Hercules, CA, USA). Equal protein amounts (60 µg) from samples were size fractionated by 6% (vol/vol) SDS/PAGE from 40% Acryl/Bisacrylamide (29/1) commercial solution, transferred to a PVDF membrane and probed with either a mouse PanNav antibody (preserved sequence of the sodium channel α-subunit III-IV loop; 1:500; clone K58/35, Sigma), a polyclonal rabbit KCC2 antibody (1:500, 07--432, Millipore), a polyclonal rabbit calpain-I antibody (1:500, 2556S, Ozyme) or a polyclonal rabbit calpain-II antibody (1:500, AB81023, Millipore) at 4°C overnight in Tris-buffered saline containing 5% fat-free milk powder. The blot was then incubated for 1 hr at 22°C with an ImmunoPure goat HRP-conjugated mouse-specific antibody (1:40,000 in blocking solution; Thermo Scientific, Waltham, MA, USA).

Calpain cleavage assay {#s4-8}
----------------------

Lumbar spinal cords were homogenized in 400 µl sucrose buffer for membrane preparation (300 mM sucrose, 10 mM Tris base, 2 mM EDTA, 0.5 mM PMSF, and 1 μM pepstatin A) and centrifuged at 7,000 g for 5 min at 4°C. The supernatant was subjected to an additional centrifugation step at 18000 g, for 70 min at 4°C, and the pellet was resuspended in the same buffer. Protein concentrations were analyzed using the Bio-Rad Dc Protein Assay. Membrane preparations were then pretreated with or without the calpain inhibitor (30 μM MDL28170, Calbiochem) for 15 min on ice. Calpain 1 (0.5 to 3 U, Calbiochem) were added for 15 min at room temperature (24°C). The reaction was stopped after addition of the electrophoresis sample buffer.

Data analysis {#s4-9}
-------------

*Softwares:* The Clampfit 10.7 software (Molecular devices) was used for analyzing electrophysiological data. The FluoView Sofware (version 5, Olympus) was used for quantifying immunostaining intensities. *Assessment of spastic motor behaviors:* For quantifying the number of twitches, the observer pressed the key of an event recorder when a twitching movement of any of the limbs and/or tail was detected. Myoclonic twitching was defined as a phasic uncontrolled movement of any part of the focal limbs and/or tail ([@bib29]). Simultaneous twitching movements of any hinlimb(s) with the tail were scored as a single twitch. Observers were careful to distinguish an active movement (e.g., kicking, twisting, and pushing). *Extracellular recordings:* EMG recordings from the triceps surae muscles were quantified by measuring the duration of the response from rectified and low pass filtered (8 Hz) digital signals. The duration was determined as the time at which the envelope of the signal exceeds a threshold. The threshold was set as the mean plus three times the standard deviation of the envelope during a period of inactivity. Threshold for mechanical stimuli was determined as the minimal pressure (weight in grams) applied to the tail for the appearance of a EMG response. At least five EMG recordings were analyzed from each animal. In response to a brief dorsal root stimulation, motor outputs recorded on the ventral roots from in vitro isolated spinal cord were quantified by cumulative counts of spikes generated in peristimulus time histograms (PSTHs; bins width: 20 ms) and calculated over a time window of 15,000 ms post-stimulation using a voltage peak detector. PSTHs were constructed from five consecutive rectified responses. We computed the transient short latency (SLR) and long-lasting reflexes (LLR) over time windows of 10--40 ms and 500--15,000 ms post-stimulus, respectively. Time windows were discretized into 20 ms-bins. For each bin, we calculated the number of events using a threshold search on ClampFit, the result was added in the corresponding time window. For each animal, we obtained one value for the SLR and one for the LLR, that were used for statistical analysis. Counts were corrected for spontaneous activity by subtracting the number of spontaneous events arising prior to the stimulus. To characterize spontaneous activities, the ventral root extracellular data were rectified integrated and smoothed with a time constant of 0.1 s. Amplitude, duration and frequency of spontaneous ventral root activities were measured with threshold-based event detection which determines the peak, the onset and end of bursts of activity. When oscillatory activities superimposed spontaneous bursts or dorsal root-evoked long-lasting reflexes, a cross-correlation analysis was performed to measure the coupling between the left and right L5 ventral bursts. The coupling was estimated by measuring the correlation coefficient at zero phase lag (center of the cross-correlogram). Positive and negative values of the correlation coefficient were representative of synchronous and out-of-phase signals, respectively. The correlation coefficient above 0.5 was taken to be indicative of synchronous activities while that below - 0.5 was taken to be indicative of a fictive locomotor episode. *Intracellular recordings:* From whole spinal cord preparations, amplitudes of IPSPs evoked in motoneurons by electrical stimulation of the ventral funiculus were measured and plotted against holding potentials. At least 22 values were collected for each motoneuron. The *E*~IPSP~ was given by the intercept of the regression line with the *x*-axis. From slice preparations, the junction potential was corrected off-line based on the composition of the internal and external solutions used for recordings. We defined the voltage-dependent activation threshold of the I~NaP~ as the membrane potential at which the slope of leak-subtracted current becomes negative. We measured the magnitude of I~NaP~ as the peak of the leak-subtracted inward current during the ascending phase of the voltage command. *Immunohistochemistry:* Measurements of Nav1.6 staining were performed on initial segments from motoneurons identified as the biggest cells located in the ventral horn. Initial segments from motoneurons were identified as large linear structures labeled by Nav1.6-specific antibodies, located in the first 10 µm of the slice within the ventral horn area, and for which the beginning and the end of the structure could be clearly determined (\>10 μm in length), excluding nodes of Ranvier. The mean pixel intensities of Nav1.6-specific fluorescence were measured by tracing the labeled initial segments using the multipoint line feature of the FluoView software. The measurements were repeated with similar numbers of motoneurons per animal. Because KCC2 is weakly expressed at the membrane of motoneurons during the first postnatal week ([@bib66]) measurements of KCC2 staining were performed in the pool of motoneurons (L4-L5) by delineating a region of interest in the lateral part of the ventral horn. The same areas were considered in successive sections. For Nav1.6 and KCC2 measurements, each value was normalized to the mean value measured from sections of SCI rats on the same slide. *Western blot:* The blots were blotted with an enhanced chemiluminescence detection (Merck-Millipore). Signal intensities were measured with the image analysis software Quantity-One (BioRad).

Drug list and solutions {#s4-10}
-----------------------

Normal aCSF was used in most cases for in vitro electrophysiological recordings. To characterize E~IPSP~, the aCSF solution composed of (in mM): 130 NaCl, 4 KCl, 3.75 CaCl~2~, 1.3 MgSO~4~, 0.58 NaH~2~PO~4~, 25 NaHCO~3~, 10 D-glucose, pH = 7.4, (24--27°C) was used. To characterize I~NaP~, the aCSF composed of the following (in mM): 100 NaCl, 3 KCl, 1.25 NaH~2~PO~4~, 1.3 MgSO~4~, 3.6 MgCl~2~, 1.2 CaCl~2~, 25 NaHCO~3~, 40 D-glucose, 10 TEA-Cl, 0.1 CdCl~2~, pH 7.4 (32--34°C) was used. Drugs were purchased from the following sources: 1,4-Dihydro-2,6-dimethyl-5-nitro-4-(2-\[trifluoromethyl\]phenyl)pyridine-3-carboxylic acid methyl ester (Bay K8644, 10 µM) ; 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, 3 µM), \[(dihydroindenyl)oxy\]alkanoic acid\] (DIOA; 30 µM), nifedipine (20 µM), tetraethylammonium chloride (TEA; 10 mM), veratridine (60 nM) from Sigma-Aldrich; MDL28170 (30 µM) from Calbiochem; 2-amino-5-phosphonovaleric acid (AP5, 30 µM), prochlorperazine dimaleate (PCPz, 10 µM) and riluzole (5 µM) from Tocris; 4,9-Anhydrotetrodotoxin (4,9-ah-TTX, 200 nM) from Focus Biomolecules. Nifedipine, DIOA, and Bay K8644 were dissolved in dimethylsulphoxide (DMSO) and added to the ACSF (final concentration of DMSO: 0.05%). Veratridine was dissolved in ethanol and added to the ACSF (final concentration of ethanol: 0.0003%). Control experiments showed no effects of the vehicle (data not shown).

Treatment design {#s4-11}
----------------

On post-operative day 4--5, rats were randomly treated with a single i.p. injection of MDL28170 (60 mg/kg or 120 mg/kg) or its vehicle. These two doses of MDL28170 were chosen because the acute systemic administration of 60 mg/kg appeared to be the minimal effective dose to produce a significant inhibition of cysteine proteinase activity in the CNS of neonatal rats ([@bib42]), while 120 mg/kg appeared to be more effective to inhibit calpain compared to the dose of 60 mg/kg ([@bib71]). The injection was performed after stable measurements of spastic motor behaviors. Regarding the pharmacokinetic profile of MDL-28170, the number of twitches was quantified as every hour up to 9 hr post-injection. The effect of the drug or its vehicle on motor responses to tail pinching was tested 1 hr post-injection.

Statistics {#s4-12}
----------

No statistical method was used to predetermine sample size. Group measurements were expressed as means ± standard deviation in figures. We used Mann-Whitney test, Wilcoxon matched pairs test to compare two groups, and a one-way or a two-way ANOVA to compare more than two groups. For all statistical analyses, the data met the assumptions of the test and the variance between the statistically compared groups was similar. The level of significance was set at p\<0.05. Statistical analyses were performed using Prism 5.0 software (Graphpad).
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

Your study convincingly demonstrates that calpain-I is upstream of Nav1.6-induced persistent activity and KCC2-related change in chloride potential; changes in both of these promote persistent motor neuron activity and spasms in neonatal rats. This is an interesting finding. Furthermore, inhibiting calpains restored expression of both, leading you to suggest calpains as a possible therapeutic target for spasticity. We congratulate you on a very elegant and important study.

**Decision letter after peer review:**

Thank you for submitting your article \"Calpain drives the excitatory-inhibitory imbalance of motoneurons and leads to spasticity after spinal cord injury\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Jan-Marino Ramirez as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Ronald Calabrese as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Rob Brownstone (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The study by provides important insights into the mechanisms leading to spasticity after SCI. Insights gained may have general implications for TBI as well. The key finding is that calpain is a critical mediator that leads to an excitatory/inhibitory imbalance in motoneurons. Although, this finding is not entirely surprising and novel, the present study brings everything together to demonstrate this link, which involves the persistent sodium current as one of the mechanisms for increased motoneuron excitability.

Title: The authors may want to reconsider the title and make it more interesting for a general readership.

Essential revisions:

1\) The authors need to provide more details with regards to the electrophysiological data. How exactly did the authors isolate the persistent sodium current. Did they use a ramp, and if so what was the time/duration and slope? The key Figure 4 doesn\'t contain much information, also with regards to the evoked inhibitory postsynaptic currents. It would be good to show the electrophysiological data in a separate figure, with more details. How were the neurons identified? Did the authors characterize these neurons anatomically and how do they know whether they were indeed recording from motoneurons?

2\) There are a few areas where clarity could be improved. It is not clear what the number of events is, for example, in Figure 3G and 3H (and similar). How do these numbers fit with the numbers of rats as reported in the legend?

3\) The notion of the excitatory-inhibitory imbalance implies a change in synaptic inputs to motoneurons. However, the main finding is mostly an upregulation of persistent Na current and consequently an increase in the excitatory of motoneurons. There is no analysis in this manuscript of how excitatory and inhibitory inputs to motoneurons are affected by spinal cord injury. Without such data, it is difficult to see how the excitatory-inhibitory balance is affected by spinal cord injury.

4\) Some data presented in this study mostly confirm earlier work in adult rats. It would be very helpful to outline in the Introduction and Discussion what has been shown in adult rats and how the present study in newborn rats differs from that in adult rats.

5\) There is a broad change in the excitability that it is not only limited to motoneurons. Do these changes also contribute to spasticity? It seems that the injury induces broad changes in the spinal cord and it is less clear what it is specific to motoneurons and what is the results of premotor interneurons. Clearly, the rhythmic activity seen in injured spinal cords does not reflect spasticity but rather an increased excitability of the premotor network. These aspects are mentioned in the Discussion, but it would be stronger if there were some direct analysis of the underlying mechanisms included.

6\) The authors should provide some explanations regarding the difference in the time course of the emergence of spasticity in newborn versus adult rats. This study reports signs of spasticity emerging within the first week after injury while in the adult it took weeks. This raises the question if the underlying mechanisms display an age-dependent difference -- some clarifications are necessary.

7\) Quantitative immunohistochemistry. It is not clear what is being measured here. There can be a great deal of variability in fluorescence from slide to slide and at different depths within a section, for example. So if it is fluorescence au\'s that are measured, how were these controlled? Furthermore if Nav-1.6 is at the IS, then is the length/area of labeling different?

8\) Bar graphs. It seems that s.e.m.\'s are depicted. It is not clear why this useless number is shown. In biology, we are concerned with variability, so the variance (standard deviation) should be shown. Furthermore, while I congratulate the authors on showing much of their data, why not show the data behind these bars with scatter plots? Then we can see the variation.

10.7554/eLife.51404.sa2

Author response

> Title: The authors may want to reconsider the title and make it more interesting for a general readership.

To make the title more relevant to a wider audience, we suggest the following title:

Calpain fosters the hyperexcitability of motoneurons after spinal cord injury and leads to spasticity.

> Essential revisions:
>
> 1\) The authors need to provide more details with regards to the electrophysiological data. How exactly did the authors isolate the persistent sodium current. Did they use a ramp, and if so what was the time/duration and slope? The key Figure 4 doesn\'t contain much information, also with regards to the evoked inhibitory postsynaptic currents. It would be good to show the electrophysiological data in a separate figure, with more details. How were the neurons identified? Did the authors characterize these neurons anatomically and how do they know whether they were indeed recording from motoneurons?

Most of details are already present in the in vitro recordings and stimulation section of Material and Methods as follows:

"The main characterization of I~NaP~ was accomplished by slow ramp increase from -70 mV to -10 mV over 5 s, slow enough (12 mV/s) to prevent transient sodium channel opening."

"Motoneurons were identified by the antidromic response to stimulation of the ventral roots. Stimulation of the ventral funiculus usually induced inhibitory postsynaptic potentials (IPSPs) in the presence of 2-amino-5-phosphonovaleric acid (AP5, 30--100 μM) and 6-cyano-7-nitroquin-oxaline-2,3-dione (CNQX, 3--10 μM). IPSPs were recorded at various holding potentials (500 ms-long current pulses)."

"Motoneurons were visually identified with video microscopy (Nikon Eclipse E600FN) coupled to infrared differential interference contrast, as the largest cells located in layer IX"

To help the reader, we added some details of the protocol in the corresponding figure legend. We also illustrated the voltage ramp protocol used for evoking I~NaP~ and the stimulus artifact for evoking IPSPs. We have not made a separate figure with the electrophysiological data because we believe their presence in Figure 4 is more useful.

> 2\) There are a few areas where clarity could be improved. It is not clear what the number of events is, for example, in Figure 3G and 3H (and similar). How do these numbers fit with the numbers of rats as reported in the legend?

To clarify this point we added the following text in each legend when it was appropriate:

"Group means quantification of: events per rat detected over time windows of 10--40 ms and 500--15,000 ms post-stimulus for SLR and LLR, respectively."

More details were also added in Material and Methods as follows:

"PSTHs were constructed from 5 consecutive rectified responses. We computed the transient short latency (SLR) and long-lasting reflexes (LLR) over time windows of 10--40 ms and 500--15,000 ms post-stimulus, respectively. Time windows were discretized into 20 ms-bins. For each bin, we calculated the number of events using a threshold search on ClampFit, the result was added in the corresponding time window. For each animal, we obtained one value for the SLR and one for the LLR, that were used for statistical analysis."

> 3\) The notion of the excitatory-inhibitory imbalance implies a change in synaptic inputs to motoneurons. However, the main finding is mostly an upregulation of persistent Na current and consequently an increase in the excitatory of motoneurons. There is no analysis in this manuscript of how excitatory and inhibitory inputs to motoneurons are affected by spinal cord injury. Without such data, it is difficult to see how the excitatory-inhibitory balance is affected by spinal cord injury.

We recognize that, as the reviewers said, to talk about the excitatory-inhibitory balance we should have studied the synaptic input onto motoneurons, which was part of our experiments concerning inhibition (See Figure 4K). However, we agree that we did not investigate changes in the excitatory inputs to motoneurons. What we are describing, instead, is the hyperexcitability of motoneurons related to the increase of the persistent sodium current, which is at the origin of spasticity and spasms that we observe. Therefore, we replaced throughout the manuscript all mentions to the "excitatory-inhibitory imbalance" by "hyperexcitability".

> 4\) Some data presented in this study mostly confirm earlier work in adult rats. It would be very helpful to outline in the Introduction and Discussion what has been shown in adult rats and how the present study in newborn rats differs from that in adult rats.

To meet the request we distinguished in the Introduction studies made in adults from those in newborns. To emphasize the novelty of our study compared to previous ones we rewrote the first paragraph of the Discussion as follows:

"Numerous studies on adult animal models delineate the hyperexcitable state of motoneurons as one of the causes of spasticity, presumably because of an increase of INaP and a decrease of KCC2 expression. The present study performed in neonatal rats identifies the activation of calpains as the upstream mechanism of the hyperexcitability of motoneurons after SCI. Calpain-mediated cleavage of Nav channels and KCC2 up- and down-regulates INaP and inhibition, respectively, in lumbar motoneurons. The reduction of calpain activity normalizes INaP and the strength of inhibitory transmission, and thereby alleviates spasticity. Altogether, these findings uncover a new cellular mechanism contributing to spasticity and provide novel therapeutic targets..."

> 5\) There is a broad change in the excitability that it is not only limited to motoneurons. Do these changes also contribute to spasticity? It seems that the injury induces broad changes in the spinal cord and it is less clear what it is specific to motoneurons and what is the results of premotor interneurons. Clearly, the rhythmic activity seen in injured spinal cords does not reflect spasticity but rather an increased excitability of the premotor network. These aspects are mentioned in the Discussion, but it would be stronger if there were some direct analysis of the underlying mechanisms included.

We agree with the reviewers, and as we already mentioned in the discussion, the hyperexcitability is likely not limited to motoneurons. As the reviewer pointed out, in some of our experiments we found a rhythmic activity in the injured spinal cord in vitro, which is most likely caused by premotor neurons and which is implicated in generating muscle spasms (Husch et al., 2012; Bellardita et al., 2017; Lin et al., 2019). We are currently working on the mechanisms underlying this phenomenon in our model. However, it is too premature to add these preliminary results in the following study, since they will be the object of an independent paper. Therefore, we think that at this point we can only discuss our data.

> 6\) The authors should provide some explanations regarding the difference in the time course of the emergence of spasticity in newborn versus adult rats. This study reports signs of spasticity emerging within the first week after injury while in the adult it took weeks. This raises the question if the underlying mechanisms display an age-dependent difference -- some clarifications are necessary.

We are grateful to the reviewers for raising this interesting point. We have described the onset of spasticity in newborn rats, which is surprisingly much faster than the onset in adult rats. We do not know exactly why is that so, but we discussed two non-exclusive mechanisms as follows:

"The emergence of spasticity is surprisingly faster than that of adult animals, which appears several weeks after the injury. A more active calpain-mediated proteolysis during early development may explain this age-dependent discrepancy. Indeed, calpain proteolysis is necessary for the pruning of axons during development (Yang et al., 2013) and the natural calpain inhibitory peptide, calpastatin, increases slowly in the CNS during the first weeks of life (Li et al., 2009). The lower presence of this inhibitor in newborn rats may explain why hyperexcitability after a neonatal SCI developed faster. Also at birth, rat motoneurons overexpress NMDA receptors (Vinay et al., 2000) which have been demonstrated to be efficient in activating calpains in pathological conditions (Zhou et al., 2012). In sum, the low expression of calpastatin combined with a high expression of NMDA receptors may contribute to a fast increase of motoneuronal excitability after a SCI in newborn rats."

The following references were added in the manuscript:

Li et al., (2009). Calpain 1 and Calpastatin expression is developmentally regulated in rat brain. Exp Neurol. 2009 Dec;220(2):316-9.doi:10.1016/j.expneurol.2009.09.004. Epub 2009 Sep 12.

Vinay et al. (2000) Perinatal development of lumbar motoneurons and their inputs in the rat. Brain Res Bull 53(5):635-47.

Yang et al. (2013) Regulation of axon degeneration after injury and in development by the endogenous calpain inhibitor calpastatin. Neuron 80(5):1175-89.

> 7\) Quantitative immunohistochemistry. It is not clear what is being measured here. There can be a great deal of variability in fluorescence from slide to slide and at different depths within a section, for example. So if it is fluorescence au\'s that are measured, how were these controlled? Furthermore if Nav-1.6 is at the IS, then is the length/area of labeling different?

Sections from treated and untreated SCI rats were mounted on the same slides and processed simultaneously. We used identical settings and quantification of staining intensities were performed using the FluoView Sofware (version 5, Olympus). Measurements were performed on AISs of biggest cells located in the first 10 µm of the slice within the ventral horn region, and for which the beginning and the end of the structure could be clearly determined (\>10 μm in length), excluding nodes of Ranvier. The mean pixel intensities of Nav1.6-specific fluorescence were measured by tracing the labelled AISs using the multipoint line feature of the FluoView software, on the optical section where the intensity of fluorescence was optimal. Each value representing the intensity of fluorescence averaged to the length of the AISs was then normalized to the mean value measured from sections of untreated SCI rats on the same slide. Analysis were performed on a similar number of motoneurons per animal. This information is originally described in data analysis section of Materials and methods.

> 8\) Bar graphs. It seems that s.e.m.\'s are depicted. It is not clear why this useless number is shown. In biology, we are concerned with variability, so the variance (standard deviation) should be shown. Furthermore, while I congratulate the authors on showing much of their data, why not show the data behind these bars with scatter plots? Then we can see the variation.

Due to the large number of samples and the small size of histograms, illustrating data with scatter plots would make the histograms unreadable. However to meet the concern we replaced all SEM by SD in figures. All SDs are also in data sources. The statistics section in the Materials and Methods was amended accordingly.

[^1]: These authors contributed equally to this work.
